Feature

Moving beyond the one-size-fits-all formula for breast cancer treatments


 

Major advances in the understanding of breast cancer biology have led to new treatment options that have dramatically improved the prognosis for breast cancer patients in the past few decades. Yet, breast cancer remains a significant health problem; in 2011 it was estimated that about 2.9 million women were living with breast cancer in the United States and median survival in the metastatic setting is only 2 years. Thus, the development of new and effective treatment options remains a priority. Here, we discuss the most significant advances in recent years that are changing oncology practice today and for the future.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Survival benefit from contralateral prophylactic mastectomy small
MDedge Hematology and Oncology
Early results show promise of topical tamoxifen for women with DCIS
MDedge Hematology and Oncology
Early results show promise of topical tamoxifen for women with DCIS
MDedge Hematology and Oncology
Encouraging data at ASCO 2014 for survival and fertility in some cancers
MDedge Hematology and Oncology
Recent use of oral contraceptives linked to breast cancer
MDedge Hematology and Oncology
PALB2 mutation increased lifetime risk of breast cancer
MDedge Hematology and Oncology
Bisphosphonates don’t cut risk of breast cancer
MDedge Hematology and Oncology
No rise in breast cancer recurrence found with TNF inhibitor use
MDedge Hematology and Oncology
Open surgery for 34% of inpatient breast biopsies
MDedge Hematology and Oncology
Breast cancer in male veteran population: an analysis from VA cancer registry
MDedge Hematology and Oncology